Editing Management of Localized Prostate Cancer (section)

===== <span style="color:#ff0000">Frequency of Testing</span> =====
* '''<span style="color:#ff0000">AUA</span>''' '''(2022 AUA Guidelines)'''
*#'''<span style="color:#ff0000">Serial PSA values: should not be obtained more frequently than every 6 months</span>'''
*#'''<span style="color:#ff0000">Symptom assessment and DRE: should be updated every 2 years</span>'''
*#'''<span style="color:#ff0000">Serial surveillance biopsies: recommended every 1-4 years depending on patient age, health, risk of progression, and preference</span>'''
*##The monitoring regimen for patients managed with active surveillance may be individualized.
*##*Among patients at low risk of progression or with a more limited life expectancy, a less intense follow-up schedule may be implemented
*##Serial genomic testing among patients on active surveillance should be discouraged.
* '''<span style="color:#ff0000">CUA</span> (2015 CUA Guideline on Prostate Cancer Active Surveillance Notes)'''
*# '''<span style="color:#ff0000">PSA every 3-6 months</span>'''
*# '''<span style="color:#ff0000">DRE every year</span>'''
*# '''<span style="color:#ff0000">Confirmatory biopsy within the initial 6-12 months, then serial biopsy a minimum of 3-5 years thereafter</span>'''
* '''None of the current active surveillance studies have found DRE to be an independent predictor of cancer progression, although it can be useful in determining that a repeat biopsy should be taken'''.